S.A. is a biotechnology company established in 1992 to promote
the clinical use of newly discovered stress proteins. Research
and development was initially focussed on the Pancreatitis-Associated
Protein (PAP), the first member of a new class of stress proteins
whose expression reflects with extreme sensitivity pathological
alterations of several tissues in the gastrointestinal tract.
partnership was established between DYNABIO S.A. and INSERM
laboratories working on such proteins and the company was
granted by INSERM (http://www.inserm.fr/)
exclusive licencing of the PAP patents covering the clinical
use of PAP antibodies and the use of the PAP assay in cystic
fibrosis neonatal screening.
ELISA for PAP was constructed and several clinical research
projects were instigated to evaluate the interest of monitoring
PAP in various pathologies. They provided ground for commercial
development of the product. The PancrePAP
kit is presently distributed worldwide and the number
of potential applications is growing (see Documentation section).
recently, demonstration in a large-scale multicenter study
that PAP assay, coupled with immunoreactive trypsinogen assay,
allowed newborn screening for cystic fibrosis (see Documentation
section) led to the development of a new kit adapted to newborn
screening, called MucoPAP.
S.A. is developing new immunological tools to improve detection
of PAP. Its facilities are located on the Luminy campus in
Marseille -France- (http://www.agl.univ-mrs.fr)
, in a very dynamic environment with strong academic research
in Immunology and a growing number of biotechnology companies.